Clinical Trials on Advanced or Refractory Solid Malignancies

Total 3583 results

Gilead Sciences

Completed

Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-cell Malignancies

France, United Kingdom
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Advanced Solid Tumors | Advanced or Metastatic Gastric Cancer | Advanced or Metastatic Gastroesophageal Junction Cancer

United States
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 in Adult Patients With Advanced Malignancies

Cancer, Advanced Malignancies

Canada, United States
Millennium Pharmaceuticals, Inc.

Completed

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Advanced Nonhematologic Malignancies

United States, Spain, France, United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies

Advanced Nonhematologic Malignancies

United States, Spain, United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C

Advanced Gastrointestinal Malignancies

United States
Millennium Pharmaceuticals, Inc.

Withdrawn

Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies

Advanced Nonhematologic Malignancies

United States
University Hospital, Bordeaux
Novartis; National Cancer Institute, France; Fondation ARC

Recruiting

Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults (SPARTO)

Refractory or Recurrent Solid Tumor

France
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Recruiting

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Refractory and/or Relapsed Metastatic Solid Tumors

United States
Merck Sharp & Dohme LLC

Completed

Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)

Relapsed or Refractory Advanced Cancer
Astellas Pharma Global Development, Inc.

Active, not recruiting

Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen

Advanced Cancer | Advanced Malignancies

United States
Washington University School of Medicine

Completed

Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies

Resistant Solid Malignancies

United States
Geron Corporation

Completed

Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies

Solid Tumor Malignancies

United States
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Not yet recruiting

Phase I Clinical Study of BR105 Injection (BR105-I)

Advanced Malignancies

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies

Advanced Malignancies

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Clinical Study of MIL93 in Solid Tumors.

Advanced Malignancies

China
BeiGene

Enrolling by invitation

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Advanced Malignancies

China, Taiwan, Korea, Republic of, Turkey
Incyte Corporation

Terminated

The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

Advanced Malignancies

United States, Italy, Denmark, Japan
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1501 in Patients With Advanced Tumors

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread

Advanced Malignancies

Japan
Millennium Pharmaceuticals, Inc.

Completed

A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors

Advanced Malignancies

United States
Infinity Pharmaceuticals, Inc.

Terminated

A Phase 1 Dose Escalation Study of IPI-493

Advanced Malignancies

United States
Mirati Therapeutics Inc.

Completed

Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State

Advanced Malignancies

United States
Novartis Pharmaceuticals

Terminated

The Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies

Advanced Malignancies

United States
Heidelberg Pharma AG
United States Department of Defense

Completed

Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies

Advanced Malignancies

United States
GeneQuantum Healthcare (Suzhou) Co., Ltd.

Recruiting

A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

HER2 Expressing or Mutated Advanced Malignant Solid Tumors

China
BeBetter Med Inc
Xiangya Hospital of Central South University

Recruiting

Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation

Advanced or Metastatic Solid Tumor | KRAS G12C Mutation

China
AstraZeneca

Active, not recruiting

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

Locally Advanced or Metastatic Solid Tumours

United States, Spain, Canada, Korea, Republic of
Gilead Sciences

Recruiting

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

Solid Malignancies

United States, Israel
Canadian Cancer Trials Group
AstraZeneca

Active, not recruiting

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Solid Malignancies

Canada
R-Pharm

Completed

Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.

Solid Malignancies

United States
University of Kentucky
Arno Therapeutics

Completed

A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies

Solid Malignancies

United States
Sigma-Tau Research, Inc.
Dana-Farber Cancer Institute; Rhode Island Hospital

Completed

This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor

Solid Malignancies

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Semafore Pharmaceuticals
SignalRX Pharmaceuticals, Inc.

Completed

A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors (SF112600106)

Cancer | Advanced or Metastatic Solid Tumors | Solid Cancers

United States
Tayu Huaxia Biotech Medical Group Co., Ltd.

Recruiting

A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas

Locally Advanced /Metastatic Solid Tumors | Relapsed or Refractory Lymphomas

China
Jiangsu Simcere Pharmaceutical Co., Ltd.

Recruiting

An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.

Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion

China
National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Acrotech Biopharma Inc.
Axis Clinicals Limited

Terminated

To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.

Relapsed/Refractory Solid Tumors/Hematological Malignancies

United States
Synta Pharmaceuticals Corp.

Completed

A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors

Solid Tumor Malignancies

United States
Washington University School of Medicine

Completed

Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies

Resistant Solid Malignancies

United States
Weill Medical College of Cornell University

Terminated

Treatment With ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies

Solid Tumor Malignancies

United States
Summa Health System

Terminated

Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy

Advanced Bulky Malignancies

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of MLN4924 in Adult Patients With Nonhematologic Malignancies

Advanced Nonhematologic Malignancies

United States
Novartis Pharmaceuticals

Completed

A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function

Advanced Malignancies | Tumors

United States
Pfizer

Terminated

A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors

Advanced Non-Hematologic Malignancies

United States, United Kingdom
Incyte Corporation

Terminated

Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

Advanced or Metastatic Solid Tumors | FGFR Mutations | FGFR Translocations

United States

Clinical Trials on Advanced or Refractory Solid Malignancies

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations